Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study

Jannik Langtved Pallisgaard; Tommi Bo Lindhardt; Morten Lock Hansen; Anne-Marie Schjerning; Jonas Bjerring Olesen; Laila Staerk; Christian Torp-Pedersen; Gunnar Hilmar Gislason

doi:10.1371/journal.pone.0141377

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study

Jannik Langtved Pallisgaard, Tommi Bo Lindhardt, Morten Lock Hansen, Anne-Marie Schjerning, Jonas Bjerring Olesen, Laila Staerk, Christian Torp-Pedersen, Gunnar Hilmar Gislason

Institut for Klinisk Medicin

25 Citationer (Scopus)

Abstract

AIM: Cardioversion can rapidly and effectively restore sinus rhythm in patients with persistent atrial fibrillation. Since 2011 dabigatran has been available as an alternative to warfarin to prevent thromboembolic events in patients with non-valvular atrial fibrillation undergoing cardioversion. We studied time to cardioversion, risk of adverse events, and risk of readmission with atrial fibrillation after cardioversion according to anticoagulation therapy.

METHODS AND RESULTS: Through the nationwide Danish registries we included 1,230 oral anticoagulation naïve patients with first time non-valvular atrial fibrillation and first time cardioversion from 2011 to 2012; 37% in the dabigatran group (n = 456), and 63% in the warfarin group (n = 774). Median time to cardioversion was 4.0 (interquartile range [IQR] 2.9 to 6.5) and 6.9 (IQR 3.9 to 12.1) weeks in the dabigatran and warfarin groups respectively, and the adjusted odds ratio of cardioversion within the first 4 weeks was 2.3 (95% confidence interval [CI] 1.7 to 3.1) in favor of dabigatran. The cumulative incidence of composite endpoint of stroke, bleeding or death were 2.0% and 1.0% at 30 weeks in the warfarin and dabigatran groups respectively, with an adjusted hazard ratio of 1.33 (95% CI 0.33 to 5.42). Cumulative incidence of readmission with atrial fibrillation after 30 weeks were 9% and 11% in the warfarin and dabigatran groups, respectively, and an adjusted hazard ratio of 0.66 (95% CI 0.41 to 1.08).

CONCLUSION: Anticoagulation treatment with dabigatran allows shorter time to cardioversion for atrial fibrillation than warfarin, and appears to be an effective and safe alternative treatment strategy to warfarin.

Originalsprog	Engelsk
Artikelnummer	e0141377
Tidsskrift	P L o S One
Vol/bind	10
Udgave nummer	10
Sider (fra-til)	1-11
Antal sider	11
ISSN	1932-6203
DOI	https://doi.org/10.1371/journal.pone.0141377
Status	Udgivet - 29 okt. 2015

Adgang til dokumentet

10.1371/journal.pone.0141377Licens: CC BY

Citationsformater

@article{4ec13800d24a4cc4a426b241aac7014b,

title = "Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study",

abstract = "AIM: Cardioversion can rapidly and effectively restore sinus rhythm in patients with persistent atrial fibrillation. Since 2011 dabigatran has been available as an alternative to warfarin to prevent thromboembolic events in patients with non-valvular atrial fibrillation undergoing cardioversion. We studied time to cardioversion, risk of adverse events, and risk of readmission with atrial fibrillation after cardioversion according to anticoagulation therapy.METHODS AND RESULTS: Through the nationwide Danish registries we included 1,230 oral anticoagulation na{\"i}ve patients with first time non-valvular atrial fibrillation and first time cardioversion from 2011 to 2012; 37% in the dabigatran group (n = 456), and 63% in the warfarin group (n = 774). Median time to cardioversion was 4.0 (interquartile range [IQR] 2.9 to 6.5) and 6.9 (IQR 3.9 to 12.1) weeks in the dabigatran and warfarin groups respectively, and the adjusted odds ratio of cardioversion within the first 4 weeks was 2.3 (95% confidence interval [CI] 1.7 to 3.1) in favor of dabigatran. The cumulative incidence of composite endpoint of stroke, bleeding or death were 2.0% and 1.0% at 30 weeks in the warfarin and dabigatran groups respectively, with an adjusted hazard ratio of 1.33 (95% CI 0.33 to 5.42). Cumulative incidence of readmission with atrial fibrillation after 30 weeks were 9% and 11% in the warfarin and dabigatran groups, respectively, and an adjusted hazard ratio of 0.66 (95% CI 0.41 to 1.08).CONCLUSION: Anticoagulation treatment with dabigatran allows shorter time to cardioversion for atrial fibrillation than warfarin, and appears to be an effective and safe alternative treatment strategy to warfarin.",

author = "Pallisgaard, {Jannik Langtved} and Lindhardt, {Tommi Bo} and Hansen, {Morten Lock} and Anne-Marie Schjerning and Olesen, {Jonas Bjerring} and Laila Staerk and Christian Torp-Pedersen and Gislason, {Gunnar Hilmar}",

year = "2015",

month = oct,

day = "29",

doi = "10.1371/journal.pone.0141377",

language = "English",

volume = "10",

pages = "1--11",

journal = "PLoS Computational Biology",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "10",

}

TY - JOUR

T1 - Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study

AU - Pallisgaard, Jannik Langtved

AU - Lindhardt, Tommi Bo

AU - Hansen, Morten Lock

AU - Schjerning, Anne-Marie

AU - Olesen, Jonas Bjerring

AU - Staerk, Laila

AU - Torp-Pedersen, Christian

AU - Gislason, Gunnar Hilmar

PY - 2015/10/29

Y1 - 2015/10/29

N2 - AIM: Cardioversion can rapidly and effectively restore sinus rhythm in patients with persistent atrial fibrillation. Since 2011 dabigatran has been available as an alternative to warfarin to prevent thromboembolic events in patients with non-valvular atrial fibrillation undergoing cardioversion. We studied time to cardioversion, risk of adverse events, and risk of readmission with atrial fibrillation after cardioversion according to anticoagulation therapy.METHODS AND RESULTS: Through the nationwide Danish registries we included 1,230 oral anticoagulation naïve patients with first time non-valvular atrial fibrillation and first time cardioversion from 2011 to 2012; 37% in the dabigatran group (n = 456), and 63% in the warfarin group (n = 774). Median time to cardioversion was 4.0 (interquartile range [IQR] 2.9 to 6.5) and 6.9 (IQR 3.9 to 12.1) weeks in the dabigatran and warfarin groups respectively, and the adjusted odds ratio of cardioversion within the first 4 weeks was 2.3 (95% confidence interval [CI] 1.7 to 3.1) in favor of dabigatran. The cumulative incidence of composite endpoint of stroke, bleeding or death were 2.0% and 1.0% at 30 weeks in the warfarin and dabigatran groups respectively, with an adjusted hazard ratio of 1.33 (95% CI 0.33 to 5.42). Cumulative incidence of readmission with atrial fibrillation after 30 weeks were 9% and 11% in the warfarin and dabigatran groups, respectively, and an adjusted hazard ratio of 0.66 (95% CI 0.41 to 1.08).CONCLUSION: Anticoagulation treatment with dabigatran allows shorter time to cardioversion for atrial fibrillation than warfarin, and appears to be an effective and safe alternative treatment strategy to warfarin.

AB - AIM: Cardioversion can rapidly and effectively restore sinus rhythm in patients with persistent atrial fibrillation. Since 2011 dabigatran has been available as an alternative to warfarin to prevent thromboembolic events in patients with non-valvular atrial fibrillation undergoing cardioversion. We studied time to cardioversion, risk of adverse events, and risk of readmission with atrial fibrillation after cardioversion according to anticoagulation therapy.METHODS AND RESULTS: Through the nationwide Danish registries we included 1,230 oral anticoagulation naïve patients with first time non-valvular atrial fibrillation and first time cardioversion from 2011 to 2012; 37% in the dabigatran group (n = 456), and 63% in the warfarin group (n = 774). Median time to cardioversion was 4.0 (interquartile range [IQR] 2.9 to 6.5) and 6.9 (IQR 3.9 to 12.1) weeks in the dabigatran and warfarin groups respectively, and the adjusted odds ratio of cardioversion within the first 4 weeks was 2.3 (95% confidence interval [CI] 1.7 to 3.1) in favor of dabigatran. The cumulative incidence of composite endpoint of stroke, bleeding or death were 2.0% and 1.0% at 30 weeks in the warfarin and dabigatran groups respectively, with an adjusted hazard ratio of 1.33 (95% CI 0.33 to 5.42). Cumulative incidence of readmission with atrial fibrillation after 30 weeks were 9% and 11% in the warfarin and dabigatran groups, respectively, and an adjusted hazard ratio of 0.66 (95% CI 0.41 to 1.08).CONCLUSION: Anticoagulation treatment with dabigatran allows shorter time to cardioversion for atrial fibrillation than warfarin, and appears to be an effective and safe alternative treatment strategy to warfarin.

U2 - 10.1371/journal.pone.0141377

DO - 10.1371/journal.pone.0141377

M3 - Journal article

C2 - 26513589

SN - 1932-6203

VL - 10

SP - 1

EP - 11

JO - PLoS Computational Biology

JF - PLoS Computational Biology

IS - 10

M1 - e0141377

ER -

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater